Oncology is set to dominate the clinical trial landscape in 2024, according to a new analysis of planned and expected studies. The analysis, derived from GlobalData’s Clinical Trials Database, reveals that oncology is the leading therapy area for both planned trial initiations and anticipated completions in the coming year.
The report, which examined clinical trials with planned start dates between January 1 and December 31, 2024, shows a significant emphasis on Phase II trials. Within this phase, most trials are slated to begin in January and are primarily sponsored by industry players. Novartis emerges as the top industry sponsor in terms of clinical trial count.
While oncology leads in planned trials, the specific indications of focus vary. Pain is the top indication for planned trials, whereas solid tumors are the leading indication for trials expected to be completed in 2024. This suggests a potential shift in research priorities or a lag time between trial initiation and completion for different indications.
Geographically, the Asia-Pacific (APAC) region is projected to have the highest number of trial completions in 2024. However, the majority of these trials are sponsored by non-industry entities, with the University of Texas MD Anderson Cancer Center leading the pack. This highlights the significant role of academic and research institutions in driving clinical research in the APAC region.
The analysis also considered various factors such as trial phase, multinational status, geography, sponsor type, therapy area, indication, drug type, and the use of decentralized clinical trial (DCT) methods. This comprehensive approach provides a detailed overview of the clinical trial landscape and identifies key trends and patterns.
These insights are based on data extracted from GlobalData’s Clinical Trials Database as of December 15, 2023, capturing trials with planned start and end dates within 2024. The data is subject to daily updates, reflecting the dynamic nature of clinical research and development.
